Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | 32 | 42 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 1 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | 27 |
Revenue
|
|||
| — | — | — | — | — | — | 0.00% | 0.00% | 0.00% | 100.00% |
Gross Margin
|
|||
| — | — | — | — | — | — | (23) | (60) | (87) | (94) |
EBT
|
|||
| — | — | — | — | — | — | 0.00% | 0.00% | 0.00% | (342.45%) |
EBT Margin
|
|||
| — | — | — | — | 0 | — | (23) | (60) | (87) | (94) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.62 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (0.69) | (6.24) | (3.23) | (2.12) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | (0.44) | (3.98) | (2.68) | (1.27) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | (0.01) | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | (0.44) | (3.99) | (2.68) | (1.28) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | 0.27 | 3.36 | 4.30 | 4.84 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 34 | 10 | 27 | 44 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 2.05 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | — | (1.28) |
EV/FCF
|
|||
| — | — | — | — | — | — | (15) | (38) | (72) | (56) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | (15) | (38) | (72) | (56) |
FCF
|
|||
| — | — | — | — | — | — | (11) | 13 | 93 | 201 |
Working Cap'
|
|||
| — | — | — | — | — | — | 20 | 0 | 0 | 10 |
Total Debt
|
|||
| — | — | — | — | — | — | 0 | (40) | (103) | (211) |
Net Debt
|
|||
| — | — | — | — | — | — | 9 | 32 | 116 | 213 |
Sh' Equity
|
|||
| — | — | — | — | — | — | (106.97%) | (104.74%) | (84.03%) | (48.18%) |
ROA
|
|||
| — | — | — | — | — | — | 0.00% | 0.00% | (402.96%) | (2,210.25%) |
ROIC
|
|||
| — | — | — | — | — | — | (113.16%) | (288.88%) | (117.39%) | (56.92%) |
ROE
|
|||
predictions in italic, sparklines do not include predictions
Fiscal years to Dec 2022
VectivBio Holding AG peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals Inc. | $537.8M | 0.0× | Compare |
| SGMT Sagimet Biosciences Inc. | $561.1M | 0.0× | Compare |
| CBIO Crescent Biopharma, Inc. | $528.9M | 0.0× | Compare |
| DRUG Bright Minds Biosciences Inc. | $527.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | $524.8M | 0.0× | Compare |
| PHAT Phathom Pharmaceuticals, Inc. | $572.8M | 0.0× | Compare |
| PROK ProKidney Corp. | $514.0M | 0.0× | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $513.7M | 0.0× | Compare |
VectivBio Holding AG (VECT) key facts
- VectivBio Holding AG (VECT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- VectivBio Holding AG’s revenue for fiscal 2022 (year ended December 2022) was $27.3 million.
- VectivBio Holding AG reported a net loss of $93.7 million, or a loss of $2.12 per share, for fiscal 2022.
- Return on equity was −56.9% and debt-to-equity 0.05.
VectivBio Holding AG (VECT) Latest News
No news matches these filters.